InterCure Ltd. (INCR) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$5.35

From 52W high−36.79%

Volume3686.00

Market cap$79.67M

P/E (TTM)—

P/S (TTM)0.9x

Div yield—

Key dataSep 18, 2026

Open

$5.35

From 52W high

−36.79%

Volume

3686.00

Market cap

$79.67M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−6.8x

P/E (TTM)

—

RSI (14)

52.5

MomentumView details →

1D Return

+0.00%

YTD Return

+16.48%

SummaryUpdated Dec 1, 2025

InterCure Ltd. (NASDAQ:INCR) is an Israeli medical cannabis company founded in 1994 and headquartered in Herzliya, Israel. The company went public on NASDAQ in January 2019. InterCure has evolved from its original incorporation to become one of the largest medical cannabis companies outside North America, focusing on pharmaceutical-grade cannabis products for medical use. The company operates primarily in Israel while expanding internationally into European markets including the UK, Germany, and Austria.

Ask drillr about InterCure Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−6.8x

EV/Sales

1.4x

P/S (TTM)

0.9x

P/B (TTM)

0.6x

ProfitabilityView details →

Gross Margin

15.06%

Net Margin

−13.22%

EBITDA Margin

−20.48%

ROE (TTM)

−9.01%

ROA (TTM)

−5.17%

Asset Turnover

0.39x

GrowthView details →

Revenue YoY

+13.13%

EPS YoY

+24.63%

FCF YoY

+211.37%

Revenue CAGR 3Y

−11.41%

EPS CAGR 3Y

+55.63%

EBITDA YoY

+30.24%

MomentumView details →

1D Return

+0.00%

YTD Return

+16.48%

1Y Return

−27.40%

RSI (14)

52.5

vs 50D SMA

+6.33%

vs 200D SMA

+11.19%

Capital & dividendView details →

Debt/Equity

0.46x

Current Ratio

1.48x

Quick Ratio

0.97x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.03

EPS Surprise

—

Beats (12Q)

0/12

Next Q EPS Est

—

Avg Surprise (4Q)

−68.35%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

270.20M

Net Income (TTM)

−35.71M

Op. CF (TTM)

31.36M

Latest newsMore news →

InterCure finalized a NIS 230 million (~US$77 million) settlement for war-related indirect damages, and plans to accelerate rehabilitation of Canndoc's Nir Oz facility.27d ago

InterCure Ltd. secured NIS 22 million in private placement financing from investors including its CEO and pharma-focused hedge funds.90d ago

Similar companies

Qianhai Health Holdings Limited00911.HK Huakang Biomedical Holdings Company Limited08622.HK Procaps Group S.A.PROC BGM Group Ltd.BGM Talphera, Inc.TLPH Cumberland Pharmaceuticals Inc.CPIX Find similar companies →

Latest newsMore news →

InterCure finalized a NIS 230 million (~US$77 million) settlement for war-related indirect damages, and plans to accelerate rehabilitation of Canndoc's Nir Oz facility.27d ago InterCure Ltd. secured NIS 22 million in private placement financing from investors including its CEO and pharma-focused hedge funds.90d ago InterCure completed the initial closing of its acquisition of Botanico, gaining exclusive access to U.S. genetics, premium brands, and AI-driven technologies.97d ago